Literature DB >> 30023090

Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?

Oluf Dimitri Røe1,2,3.   

Abstract

Entities:  

Year:  2018        PMID: 30023090      PMCID: PMC6036040          DOI: 10.21037/jtd.2018.06.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  39 in total

Review 1.  Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.

Authors:  Christopher Cao; David H Tian; Kristopher A Pataky; Tristan D Yan
Journal:  Lung Cancer       Date:  2013-06-13       Impact factor: 5.705

Review 2.  Diagnosis and prognosis-review of biomarkers for mesothelioma.

Authors:  Huan H Sun; Allen Vaynblat; Harvey I Pass
Journal:  Ann Transl Med       Date:  2017-06

3.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

Authors:  Nico van Zandwijk; Nick Pavlakis; Steven C Kao; Anthony Linton; Michael J Boyer; Stephen Clarke; Yennie Huynh; Agata Chrzanowska; Michael J Fulham; Dale L Bailey; Wendy A Cooper; Leonard Kritharides; Lloyd Ridley; Scott T Pattison; Jennifer MacDiarmid; Himanshu Brahmbhatt; Glen Reid
Journal:  Lancet Oncol       Date:  2017-09-01       Impact factor: 41.316

4.  Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Authors:  Jenette Creaney; Nola J Olsen; Fraser Brims; Ian M Dick; Arthur W Musk; Nicholas H de Klerk; Steven J Skates; Bruce W S Robinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-22       Impact factor: 4.254

5.  hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Sergey Ivanov; Jessica Donington; Michele Carbone; Moshe Hoshen; Dalia Cohen; Ayelet Chajut; Shai Rosenwald; Harel Dan; Sima Benjamin; Ranit Aharonov
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

6.  Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

Authors:  Oluf Dimitri Roe; Jenette Creaney; Steinar Lundgren; Erik Larsson; Helmut Sandeck; Paolo Boffetta; Tom Ivar Nilsen; Bruce Robinson; Kristina Kjaerheim
Journal:  Lung Cancer       Date:  2008-02-20       Impact factor: 5.705

7.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

8.  Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis.

Authors:  Yi Zhuo; Lanying Lin; Shushan Wei; Mingwei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

9.  Calretinin as a blood-based biomarker for mesothelioma.

Authors:  Georg Johnen; Katarzyna Gawrych; Irina Raiko; Swaantje Casjens; Beate Pesch; Daniel G Weber; Dirk Taeger; Martin Lehnert; Jens Kollmeier; Torsten Bauer; Arthur W Musk; Bruce W S Robinson; Thomas Brüning; Jenette Creaney
Journal:  BMC Cancer       Date:  2017-05-30       Impact factor: 4.430

10.  Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Authors:  Michaela B Kirschner; Emily Pulford; Mir Alireza Hoda; Anita Rozsas; Kim Griggs; Yuen Yee Cheng; J James B Edelman; Steven C Kao; Rebecca Hyland; Yawen Dong; Viktoria László; Thomas Klikovits; Michael P Vallely; Michael Grusch; Balazs Hegedus; Balazs Dome; Walter Klepetko; Nico van Zandwijk; Sonja Klebe; Glen Reid
Journal:  Br J Cancer       Date:  2015-08-11       Impact factor: 7.640

View more
  1 in total

1.  Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.

Authors:  Vincenzo Fontana; Maria Pia Pistillo; Antonella Vigani; Pier Aldo Canessa; Giovanni Berisso; Ugo Giannoni; Paola Ferro; Maria Cristiana Franceschini; Roberta Carosio; Marika Tonarelli; Paolo Dessanti; Silvio Roncella
Journal:  Oncol Lett       Date:  2020-12-18       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.